Advertisement

Reactions Weekly

, Volume 1723, Issue 1, pp 23–23 | Cite as

Adalimumab/infliximab/tocilizumab

Psoriasis, worsening of psoriasis and chronic recurrent multifocal osteomyelitis: 5 case reports
Case report
  • 10 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series, 5 children aged 5−12 years were described, who developed psoriasis during treatment with infliximab or adalimumab for chronic recurrent multifocal osteomyelitis (CRMO). Of them, one child also experienced worsening of CRMO due to tocilizumab and worsening of psoriasis due to adalimumab.

Case 1: An almost 5-year-old girl was diagnosed with CRMO. She was started on treatment with IV infliximab 10-20mg/kg every 3−4 weeks, methotrexate and pamidronic acid [pamidronate]. Five months after initiation of this treatment, she developed well-demarcated erythematous papules and annular plaques studded with pustules on her neck, back and extremities with significant scalp involvement and alopecia, which was consistent with psoriasis. Therefore, infliximab was stopped. She...

Reference

  1. Campbell JA, et al. Case series of psoriasis associated with tumor necrosis factor-alpha inhibitors in children with chronic recurrent multifocal osteomyelitis. JAAD Case Reports 4: 767-771, No. 8, Sep 2018. Available from: URL: http://doi.org/10.1016/j.jdcr.2018.06.008 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations